GLIS2 and acute myeloid leukemia: We utilized this model to test JAK inhibition using ruxolitinib and tofacitinib, comparing cells briefly cultured in vitro to that of cells from three other PDX models: one harboring the CBFA2T3::GLIS2 fusion (2016–35) and two lacking this fusion (16 – 01 and 17 – 14) (AML model characteristics in Supplemental Table S1).